A Decade of Direct-to-Consumer Advertising of Prescription Drugs.¶
Donohue, J. M., Cevasco, M., & Rosenthal, M. B. (2007). A Decade of Direct-to-Consumer Advertising of Prescription Drugs. New England Journal of Medicine, 357(7), 673-681.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Primes¶
- Summary Substance Divergence
- In drug labeling it is the front-of-package efficacy claim versus the patient leaflet — marketing optimizing the front, regulatory affairs the back.
This sourceDocuments the marketing-authored promotional surface of drugs (DTC advertising emphasizing benefits over risks) diverging from the regulatory-authored disclosure — the front-of-package/talking-point versus leaflet/filing divergence.
Supported in partVerified against the work's full text
The paper documents FDA findings that drug ads minimised risks and exaggerated effectiveness relative to the label, but not package-front claims versus patient leaflets.
“advertisement for Zoloft (sertraline) was false or misleading because it omitted important information relating to the risk of suicidality in patients”
- In drug labeling it is the front-of-package efficacy claim versus the patient leaflet — marketing optimizing the front, regulatory affairs the back.
Verification¶
Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:876884d5eb2f · see in the full table